Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
21 June 2021
Regulatory reform for software-based consumer health - Can rules keep up with reality?
26 May 2021
Australian Consumer Law marks 10 years with some large penalties
13 April 2021
Pharmaceutical patent term extensions: federal court hears challenge to “absurd” Australian patent office ruling
11 March 2021
A ‘new normal’ when it comes to the TGA regulation of medical devices?
8 March 2021
Asia Pacific M&A Review 2021
26 February 2021
Judicial review and the life sciences and health sectors
24 February 2021
2020 Australian IPO Review: Key themes
24 February 2021
2020 Australian IPO Review: IPOs by the numbers
16 February 2021
Patent and Pharma update, February 2021
8 February 2021
Healthcare as an Infrastructure asset
28 January 2021
THE IMPACT OF THE NEW ITALIAN FOREIGN INVESTMENTS RULES ON THE PHARMA SECTOR
9 December 2020
The arrival of the Omnibus
